MAPT and early-onset autosomal dominant Alzheimer disease: Tauvid ([18F]-Flortaucipir) was approved by the U.S. Food and Drug Administration (FDA) in 2020 for PET imaging of adult patients with cognitive impairments undergoing evaluation for Alzheimer′s disease (AD) based on Tau pathology [76].